FILSPARI sales surge past $200 million as CEO plans exit
- FILSPARI is approved for IgAN and FSGS, giving Travere one main drug with two rare kidney disease markets.
- Management sees more than 100,000 eligible U.S. patients and a $3 billion peak sales chance for FILSPARI.
- Q3 2026 FILSPARI net sales reached $200.2 million, driven by 1,930 new patient start forms across both indications.
- New patents issued in Q3 2026 extend FILSPARI exclusivity in the U.S. into 2037.
- CEO Eric Dube will step down in December 2026, introducing operational risk during the dual-indication commercial ramp.
One drug, extended patents, new obstacles
Travere remains a FILSPARI execution story. The drug sells for IgA nephropathy, or IgAN, a kidney disease that can lead to kidney failure. In April 2026, the FDA also approved FILSPARI for focal segmental glomerulosclerosis, or FSGS. That turned one product into a two-market launch, and Q3 2026 sales hit a record $200.2 million on the back of 1,930 patient start forms.
The bull case relies on that momentum and stronger patent protection. Management says more than 100,000 U.S. patients could be eligible across both conditions and sees a $3 billion peak sales chance. New patents extend U.S. exclusivity into 2037, giving the company more time to realize that value. Travere also expects to submit a regulatory application for civorebrutinib in late 2026 to expand the pipeline.
The bear case centers on execution barriers and a major leadership change. CEO Eric Dube is stepping down in December 2026, handing the reins to a new leader during the most critical phase of the FSGS launch. Furthermore, early FSGS prescriptions show wide breadth but lack depth, meaning many doctors are only trying it on a single patient. The company also faces pressure to fix its supply chain after a key manufacturer was targeted by the BIOSECURE Act.
The next test is how the incoming CEO handles these hurdles. Investors will be watching whether the supply chain shift causes delays and whether the sales team can turn trial prescriptions into broader adoption.
Selling rare disease drugs
Travere makes money mostly by selling approved drugs in the U.S. Its main product is FILSPARI. It also sells Thiola and Thiola EC for cystinuria, a rare disorder that causes kidney stones, though those older drugs face generic competition.
Outside the U.S., Travere licenses sparsentan rights to CSL Vifor and Chugai. Those deals can bring in milestones and royalties, which are high-value revenue streams if partner sales grow.
The model works best when a rare disease drug has strong patent protection, clear payer coverage, and a reliable supply chain. It breaks if launch uptake is slower than expected, if insurers push back, or if reliance on third-party manufacturers causes supply disruptions.
What Travere sells and studies
FILSPARI for IgAN
FILSPARI is approved to slow kidney function decline in adults with IgAN at risk of progression. It is the base of Travere's current growth.
FILSPARI for FSGS
The FDA granted full approval on April 13, 2026, for certain FSGS patients aged 8 years and older. The company recently secured patents extending exclusivity to 2037.
Thiola and Thiola EC
These tiopronin products treat cystinuria. They produced $20.0 million of Q3 2026 net product revenue, but several approved generics make this a shrinking profit support over time.
Civorebrutinib
Licensed from Everest Medicines in June 2026, this oral BTK inhibitor is targeted for rare immune-mediated kidney diseases. A regulatory filing is expected in late 2026.
Pegtibatinase
Pegtibatinase is in the Phase 3 HARMONY study for classical homocystinuria, a rare metabolic disease. Topline data is expected in the second half of 2027.
Q3 revenue mix
Travere reports as one operating segment. This mix uses Q3 2026 revenue by product and type. FILSPARI grew to 89 percent of total Q3 revenue, showing extreme reliance on a single asset.
What could break the story
Leadership transition stumbles
High impact · Medium oddsCEO Eric Dube is leaving the company in December 2026. A change in leadership during the critical dual-indication commercial ramp for FILSPARI could disrupt execution or change capital allocation priorities.
FSGS depth fails to materialize
High impact · Medium oddsWhile early FSGS prescribing shows wide breadth, many doctors have only written scripts for a single patient. If the sales team cannot convince these doctors to prescribe FILSPARI more broadly, the addressable market will be capped.
Supply chain disruptions
High impact · Medium oddsThe primary supplier for the active ingredient in FILSPARI was added to a restricted list under the BIOSECURE Act. Travere must qualify alternative sources quickly to avoid supply shortages or higher costs.
Marketing claims pullback
Medium impact · Medium oddsThe FDA issued an untitled letter in July 2026 over FILSPARI marketing materials. This could slow launch momentum if the company has to pull back its sales messaging or retrain its sales force.
Thiola fades faster than planned
Medium impact · High oddsThiola and Thiola EC still help fund the company. Several generic versions are approved, so sales could erode faster and leave a gap before FILSPARI fully offsets the decline.
In one breath
What does Travere Therapeutics do?
Travere develops and sells drugs for rare kidney and metabolic diseases. Its main product is FILSPARI, which is approved for IgAN and certain FSGS patients.
Why does FILSPARI matter so much to TVTX stock?
FILSPARI is the main growth engine. Management sees a $3 billion peak sales chance across its two indications, so the stock depends heavily on whether that launch keeps growing.
What is the BIOSECURE Act risk for Travere?
The primary supplier for FILSPARI's active ingredient was placed on a restricted list under the BIOSECURE Act. Travere is now working to find and qualify new suppliers to avoid drug shortages.
Why is the leadership transition a risk?
CEO Eric Dube is stepping down in December 2026. The new CEO, Bradley, will need to prove he can maintain commercial execution during a critical growth phase for FILSPARI.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Travere Therapeutics, Inc. in Finn's Biotechnology industry ranking.

